• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Abivax SA - American Depositary Shares (NQ:ABVX)

    144.65 +12.09 (+9.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Abivax SA - American Depositary Shares

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
    From Abivax
    Via GlobeNewswire
    News headline image
    Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax announces trading resumption of its ordinary shares on Euronext Paris
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Announces Launch of Public Offering of American Depositary Shares
    From Abivax
    Via GlobeNewswire
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares... 
    Via Benzinga
    News headline image
    Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
    From Abivax
    Via GlobeNewswire
    News headline image
    ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead? ↗
    A recent dip may turn out to be a great opportunity. 
    Via The Motley Fool
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Which stocks are moving after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
    From Abivax
    Via GlobeNewswire
    News headline image
    Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
    From Abivax
    Via GlobeNewswire
    News headline image
    2 Stocks That Could Realistically Double by 2030 ↗
    Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead. 
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
    This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
    Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
    Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.